This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Tanaka, K. Articles by Nishino, N. Search for Related Content PubMed PubMed Citation Articles by Tanaka, K. Articles by Nishino, N.

Hepatitis C and Hepatitis B in the Etiology of Hepatocellular Carcinoma in the Japanese Population¹

Department of Public Health [K. Ta., T. H.], the First Department [H. I.] and the Third Department [H. N.] of Internal Medicine, and the Second Department of Surgery [K. S., T. K.], Kyushu University School of Medicine, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812; Iizuka Hospital, 3-83 Yoshiomachi, Iizuka-shi 820 [S. K.]; Health Promotion Section, Bureau of Public Health of Fukuoka City, 1-8-1 Tenjin, Chuo-ku, Fukuoka 810 [F. O.]; Fukuoka Red Cross Blood Center, 232-11 Oazakamikoga, Chikushino-shi 818 [Y. M., H. K., K. To., Y. I.]; Department of Information and Management Science, Tokai University Fukuoka Junior College, 1137 Taku, Munakatashi 811-41 [S. T.]; and Hakata Public Health Center, 1-21-16 Chiyo, Hakata-ku, Fukuoka 812 [Y. A., N. N.], Japan

We conducted case-control studies of hepatocellular carcinoma (HCC) and liver cirrhosis (LC) in relation to hepatitis C virus (HCV) and hepatitis B virus infection, involving 91 patients with HCC, 75 patients with LC who had no evidence of HCC, and 410 control subjects from the Japanese population. Serum antibody to HCV (anti-HCV) was detected by both enzyme-linked immunosorbent assay and recombinant immunoblot assay in 51, 51, and 3% of HCC, LC, and controls, respectively, whereas the corresponding prevalence of serum hepatitis B surface antigen (HBsAg) was 21, 11, and 2%, respectively. The relative risks (and 95% confidence intervals) for the presence of serum anti-HCV were estimated as 52.3 (23.9–114.3) for HCC and 64.4 (27.4–151.4) for LC. These values exceeded the relative risk of HCC (15.3) and that of LC (6.1) for positive serum HBsAg. Among male patients with HCC or LC, anti-HCV rates were very high in blood recipients (about 70%), heavy drinkers (46–62%), and those who had no identifiable risk factors (65–75%), indicating possible transmission of HCV via routes other than transfusion. No significant difference in anti-HCV status was observed between the HCC and LC groups. It was notable that anti-HCV was much less prevalent among HBsAg-positive patients with HCC or LC than among HBsAg-negative ones. There was a slight to moderate increase in HCC or LC risk among blood recipients and heavy drinkers after adjustment for anti-HCV status. These results indicate that, in Japan, the possible role of HCV infection in the etiology of HCC and LC is extremely large and seems to be more important than chronic hepatitis B virus infection.

¹ This work was supported in part by grants from the Ministry of Health and Welfare, the Ministry of Education, Science and Culture (60480195), Japan, and the Fukuoka Cancer Society.

² To whom requests for reprints should be addressed.

Received 9/17/90. Accepted 3/18/91.

This article has been cited by other articles:

				D. Schottenfeld and J. Beebe-Dimmer Chronic inflammation: a common and important factor in the pathogenesis of neoplasia. CA Cancer J Clin, March 1, 2006; 56(2): 69 - 83. [Abstract] [Full Text] [PDF]

				T. Chiba, K. Tokuuye, Y. Matsuzaki, S. Sugahara, Y. Chuganji, K. Kagei, J. Shoda, M. Hata, M. Abei, H. Igaki, et al. Proton Beam Therapy for Hepatocellular Carcinoma: A Retrospective Review of 162 Patients Clin. Cancer Res., May 15, 2005; 11(10): 3799 - 3805. [Abstract] [Full Text] [PDF]

				K. Shibuya and E. Yano Regression analysis of trends in mortality from hepatocellular carcinoma in Japan, 1972-2001 Int. J. Epidemiol., April 1, 2005; 34(2): 397 - 402. [Abstract] [Full Text] [PDF]

				Y. Miyanari, M. Hijikata, M. Yamaji, M. Hosaka, H. Takahashi, and K. Shimotohno Hepatitis C Virus Non-structural Proteins in the Probable Membranous Compartment Function in Viral Genome Replication J. Biol. Chem., December 12, 2003; 278(50): 50301 - 50308. [Abstract] [Full Text] [PDF]

				C.-A. Sun, D.-M. Wu, C.-C. Lin, S.-N. Lu, S.-L. You, L.-Y. Wang, M.-H. Wu, and C.-J. Chen Incidence and Cofactors of Hepatitis C Virus-related Hepatocellular Carcinoma: A Prospective Study of 12,008 Men in Taiwan Am. J. Epidemiol., April 15, 2003; 157(8): 674 - 682. [Abstract] [Full Text] [PDF]

				B. D. Spiess Blood transfusion: the silent epidemic Ann. Thorac. Surg., November 1, 2001; 72(5): S1832 - 1837. [Abstract] [Full Text] [PDF]

				K. Tanaka, H. Sakai, M. Hashizume, and T. Hirohata Serum Testosterone:Estradiol Ratio and the Development of Hepatocellular Carcinoma among Male Cirrhotic Patients Cancer Res., September 1, 2000; 60(18): 5106 - 5110. [Abstract] [Full Text]

				Prevention of Cancer in the Next Millennium: Report of the Chemoprevention Working Group to the American Association for Cancer Research Cancer Res., October 1, 1999; 59(19): 4743 - 4758. [Full Text] [PDF]

				H Marusawa, Y Osaki, T Kimura, K Ito, Y Yamashita, T Eguchi, M Kudo, Y Yamamoto, H Kojima, H Seno, et al. High prevalence of anti-hepatitis B virus serological markers in patients with hepatitis C virus related chronic liver disease in Japan Gut, August 1, 1999; 45(2): 284 - 288. [Abstract] [Full Text] [PDF]

				H. Marusawa, M. Hijikata, T. Chiba, and K. Shimotohno Hepatitis C Virus Core Protein Inhibits Fas- and Tumor Necrosis Factor Alpha-Mediated Apoptosis via NF-kappa B Activation J. Virol., June 1, 1999; 73(6): 4713 - 4720. [Abstract] [Full Text]

				H. Tsukuma, T. Hiyama, S. Tanaka, M. Nakao, T. Yabuuchi, T. Kitamura, K. Nakanishi, I. Fujimoto, A. Inoue, H. Yamazaki, et al. Risk Factors for Hepatocellular Carcinoma among Patients with Chronic Liver Disease N. Engl. J. Med., June 24, 1993; 328(25): 1797 - 1801. [Abstract] [Full Text]